qfx

AWS demonstrated robust growth in the fourth quarter of 2025, reporting a 24% year-over-year revenue increase. While Amazon possesses internal hardware design capabilities, the complexity and capital intensity of developing a complete AI hardware ecosystem necessitate reliance on external providers. Nvidia currently occupies a dominant position in this landscape.

The S&P 500 is hitting highs, sure. But that doesn’t mean this AI stuff is any different. It just means people are easily distracted. They see a shiny new toy and suddenly forget all the basic principles of investing. It’s like they’ve never seen a pump-and-dump before. Honestly, it’s insulting.

To speak of Taiwan Semiconductor Manufacturing (TSM 4.23%) is to speak of a near-total dominion. It is a position achieved not through superior vision, but through the relentless, unforgiving demands of a process – the fabrication of logic chips – that few others possess the capital, the expertise, or, frankly, the will to master. The shrinking of nodes, the pursuit of density… these are not merely technical challenges, but acts of attrition, slowly eliminating competitors, concentrating power into fewer and fewer hands. The foundries, those vast, humming cathedrals of silicon, require near-constant utilization to justify their existence – a precarious balance, demanding a constant flow of orders, a dependence that TSMC has skillfully cultivated.

exist. Consistently. Year after year. It’s a pharmaceutical leviathan, a medical device behemoth, and a consumer goods juggernaut all rolled into one. Frankly, it’s terrifying. They’re in everything, touching every aspect of the healthcare system. Patent cliffs? Drug price negotiations? They shrug it off like a minor inconvenience. They’ll hit $100 billion in revenue this year, they say. A hundred BILLION. The sheer audacity of it all. And their balance sheet? Stronger than the U.S. government’s. That should tell you something. Something deeply unsettling. They’re launching new products, robotic surgery systems, clinical trials… it’s a relentless cycle of innovation and expansion. A Dividend King, they call themselves. Fifty consecutive years of dividend hikes. FIFTY. It’s a monument to corporate inertia, a testament to their ability to squeeze profits out of every conceivable angle. It’s not pretty. It’s not glamorous. But it’s effective. And in this twisted game we call finance, effectiveness is all that matters.

This momentary rise, you see, was not born of robust trade winds or shrewd navigation, but rather the arrival of Elliott Management, an activist hedge fund with a near-10% stake. They presented a… shall we say, ‘assessment’ – a document filled with promises of improvement, as if one could simply order a cruise line to perform better. It was a presentation, one suspects, composed of more hope than actual analysis, like a map drawn by a seagull.

A recent study – a surprisingly rigorous undertaking, given the general state of things – by Hartford Funds, in collaboration with Ned Davis Research, suggests that dividend-paying stocks have, over the long haul (1973-2024, to be precise), outperformed non-dividend payers by a significant margin: 9.2% versus 4.31% annualized. This, of course, doesn’t prove anything, merely suggests a correlation. It could, for instance, be that successful companies are simply better at both generating profits and remembering to send checks. A thought, isn’t it?